LY-3022855

N/A

Report date: 2025/11/11 20:00:28

Base Information

Drug NameLY-3022855
Drug Alias NameIMC-CS4LY-3022855
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionColony stimulating factor 1 receptor inhibitors
TargetsColony stimulating factor 1 receptor
Therapy Area/IndicationsSolid tumoursNeoplasm MetastasisPancreatic Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumUnited States +[4] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesEli Lilly And Company
Inactive CompaniesDana-Farber Cancer Institute
Active IndicationsPancreatic Neoplasms
Inactive IndicationsSolid tumoursNeoplasm MetastasisMelanoma +[4] 

Other Information

ATC CodeN/A
Related LinksN/A